Mitochondrial toxicity in the era of HAART: Evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Montaner, Julio S G ^a   Côté, Hélène C F ^a   Harris, Marianne ^a   Hogg, Robert S ^a   Yip, Benita ^a   Chan, Jennifer W ^a   Harrigan, P Richard ^a   O'Shaughnessy, Michael V ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

HIV therapy; Mitochondrial DNA; Mitochondrial toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; DNA DIRECTED DNA POLYMERASE GAMMA; LACTIC ACID; LAMIVUDINE; MITOCHONDRIAL DNA; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ABDOMINAL PAIN; CARDIOMYOPATHY; CLINICAL FEATURE; CONFERENCE PAPER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG FATALITY; DYSPNEA; FATIGUE; FATTY LIVER; GENDER; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MITOCHONDRIAL TOXICITY; MUSCLE WEAKNESS; NAUSEA; OBESITY; PANCREATITIS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, MITOCHONDRIAL; HIV INFECTIONS; HUMANS; LACTATES; MITOCHONDRIA;

EID: 0141458253     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00013     Document Type: Conference Paper

References (35)

1. Powderly WG. Long-term exposure to lifelong therapies. JAIDS 2002;29:S28-S40.
2. Martin JL, Brown CE, Matthews-Davis N, et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-2749.
3. Johnson AA, Ray AS, Hanes JW, et al. Toxicity of nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001;276:40847-50857.
4. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-510.
5. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-1744.
6. Harris M, Tesiorowski A, Chan K, et al. Lactic acidosis complicating antiretroviral therapy: frequency and correlates [abstract]. Antiviral Ther 2000;5(Suppl 2):31.
7. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-723.
8. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001;33:1931-1937.
9. + patients under antiretroviral therapy [abstract 520]. Presented at the 1st International AIDS conference on HIV pathogenesis and treatment, Buenos Aires, Argentina, 2001.
10. Delgado J, Harris M, Tesiorowski A, et al. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin Infect Dis 2001;33:2072-2074.
11. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001;15:795-797.
12. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002;15:23-29.
13. Côté HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-820.
14. Côté HC, Yip B, Chan JW, et al. Preserved mitochondrial/nuclear (mt/n) DNA ratios in peripheral blood cells from HIV-infected individuals on stavudine-sparing regimens [abstract 1304]. Presented at the XIV International AIDS Conference, Barcelona, Spain, 2002.
15. Zaera MG, Miro O, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001;15:1643-1651.
16. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001;81:1537-1544.
17. Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001;15:1801-1809.
18. Lonergan JT, Havlir D, Barber E, et al. Incidence of symptomatic hyperlactatemia in HIV-infected adults on NRTIs [abstract 35]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, U.S.A., 2002.
19. Côté HCF, Negredo E, Ruiz L, et al. Antiretroviral regimen-dependent mitochondrial DNA depletion in clinical samples from the SWATCH trial [abstract 707-T]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle WA, U.S.A., 2002.
20. Mégarbane B, Brivet F, Guérin JM, et al. Acidose lactique et défaillance multiviscérale secondaire aux thé rapeutiques antirétrovirales chez les patients infectés par le VIH. Presse Med 1999;28:2257-2264.
21. Mokrzycki MH, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000;30:198-200.
22. Coghlan ME, Sommadossi J-P, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A report of 12 cases. Clin Infect Dis 2001;33:1914-1921.
23. Brinkman K, Troost N, Schrijnders L, et al. Usefulness of routine lactate measurement to prevent lactic acidosis: evaluation of a protocol [abstract 709-T]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, U.S.A., 2002.
24. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-1105.
25. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS 1997;11:1294-1296.
26. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue induced lactic acidosis. Lancet 1998;352:291-292.
27. Luzatti R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet 1999;353:901-902.
28. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral toxicity? Curr Opin Infect Dis 2000;13:5-11.
29. Brinkman K, Vrouenraets S, Kauffmann R, et al. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000;14:2801-2803.
30. Campos Y, Huertas R, Lorenzo G, et al. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993;6:150-153.
31. Dalton SD, Rahimi AR. Emerging role of riboflavin in the treatment of nucleoside analogue induced type B lactic acidosis. AIDS Patient Care STDs 2001;15:611-614.
32. Famularo G, Moretti S, Marcelline S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997;11:185-190.
33. Martin JL, Brown CE, Matthews-Davis N, et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-2749.
34. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001;276:40847-40857.
35. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-723.